Dominique Schols

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8739642/publications.pdf

Version: 2024-02-01

431 papers	22,852 citations	11235 73 h-index	14386 132 g-index
467 all docs	467 docs citations	467 times ranked	20787 citing authors

#	Article	IF	Citations
1	Itaconic acid hybrids as potential anticancer agents. Molecular Diversity, 2022, 26, 1-14.	2.1	9
2	Discovery of (â€‰Â±)-3-(1H-pyrazol-1-yl)-6,7-dihydro-5H-[1,2,4]triazolo[3,4-b][1,3,4] thiadiazine derivatives with promising in vitro anticoronavirus and antitumoral activity. Molecular Diversity, 2022, 26, 1357-1371.	2.1	11
3	Lung Microenvironments and Disease Progression in Fibrotic Hypersensitivity Pneumonitis. American Journal of Respiratory and Critical Care Medicine, 2022, 205, 60-74.	2.5	17
4	Atypical response to bacterial coinfection and persistent neutrophilic bronchoalveolar inflammation distinguish critical COVID-19 from influenza. JCI Insight, 2022, 7, .	2.3	38
5	Anthranilamides with quinoline and Î²-carboline scaffolds: design, synthesis, and biological activity. Molecular Diversity, 2022, 26, 2595-2612.	2.1	3
6	Synthesis, in vitro cytotoxicity,Âmolecular docking and ADME study of some indolin-2-one linked 1,2,3-triazole derivatives. Computational Biology and Chemistry, 2022, 97, 107641.	1.1	4
7	Targeting chemokine receptors from the inside-out: discovery and development of small-molecule intracellular antagonists. Chemical Communications, 2022, 58, 4132-4148.	2.2	7
8	Innate Lymphoid Cells Are Required to Induce Airway Hyperreactivity in a Murine Neutrophilic Asthma Model. Frontiers in Immunology, 2022, 13, 849155.	2.2	7
9	Identification of novel chemotypes as CXCR2 antagonists via a scaffold hopping approach from a thiazolo[4,5-d]pyrimidine. European Journal of Medicinal Chemistry, 2022, 235, 114268.	2.6	7
10	In silico design, synthesis and anti-HIV activity of quinoline derivatives as non-nucleoside reverse transcriptase inhibitors (NNRTIs). Computational Biology and Chemistry, 2022, 98, 107675.	1.1	6
11	A Set of Experimentally Validated Decoys for the Human CC Chemokine Receptor 7 (CCR7) Obtained by Virtual Screening. Frontiers in Pharmacology, 2022, 13, 855653.	1.6	2
12	Effect of Particle Carriers for Intraperitoneal Drug Delivery on the Course of Ovarian Cancer and Its Immune Microenvironment in a Mouse Model. Pharmaceutics, 2022, 14, 687.	2.0	4
13	Discovery of 2-Phenylquinolines with Broad-Spectrum Anti-coronavirus Activity. ACS Medicinal Chemistry Letters, 2022, 13, 855-864.	1.3	10
14	SARS-CoV-2 Virion Infectivity and Cytokine Production in Primary Human Airway Epithelial Cells. Viruses, 2022, 14, 951.	1.5	6
15	Stimulation of the atypical chemokine receptor 3 (ACKR3) by a small-molecule agonist attenuates fibrosis in a preclinical liver but not lung injury model. Cellular and Molecular Life Sciences, 2022, 79, 293.	2.4	1
16	Organotropic dendrons with high potency as HIV-1, HIV-2 and EV-A71 cell entry inhibitors. European Journal of Medicinal Chemistry, 2022, 237, 114414.	2.6	1
17	The discovery of Zika virus NS2B-NS3 inhibitors with antiviral activity via an integrated virtual screening approach. European Journal of Pharmaceutical Sciences, 2022, 175, 106220.	1.9	7
18	New 2-alkylthio-1-benzylimidazole-5-carboxylic acid derivatives targeting gp41: design, synthesis and in vitro anti-HIV activity evaluation. Current HIV Research, 2022, 20, .	0.2	0

#	Article	IF	Citations
19	Potent neutralizing anti-SARS-CoV-2 human antibodies cure infection with SARS-CoV-2 variants in hamster model. IScience, 2022, 25, 104705.	1.9	8
20	Î³â€Nonâ€Symmetrically Dimasked TriPPPro Prodrugs as Potential Antiviral Agents against HIV. ChemMedChem, 2021, 16, 499-512.	1.6	15
21	Synthesis, Molecular Docking and Preliminary Antileukemic Activity of 4â€Methoxybenzyl Derivatives Bearing Imidazo[2,1â€b][1,3,4]thiadiazole. Chemistry and Biodiversity, 2021, 18, e2000800.	1.0	3
22	Palladium-catalyzed cross-coupling reactions on a bromo-naphthalene scaffold in the search for novel human CC chemokine receptor 8 (CCR8) antagonists. Bioorganic Chemistry, 2021, 107, 104560.	2.0	2
23	In Vitro Characterization of the Carbohydrate-Binding Agents HHA, GNA, and UDA as Inhibitors of Influenza A and B Virus Replication. Antimicrobial Agents and Chemotherapy, 2021, 65, .	1.4	8
24	Synthesis, in silico ADME, molecular docking and in vitro cytotoxicity evaluation of stilbene linked 1,2,3-triazoles. Heliyon, 2021, 7, e05893.	1.4	3
25	Targeted disruption of piâ€“pi stacking in Malaysian banana lectin reduces mitogenicity while preserving antiviral activity. Scientific Reports, 2021, 11, 656.	1.6	16
26	FOâ€SPR biosensor calibrated with recombinant extracellular vesicles enables specific and sensitive detection directly in complex matrices. Journal of Extracellular Vesicles, 2021, 10, e12059.	5.5	10
27	A novel experimental porcine model to assess the impact of differential pulmonary blood flow on ischemiaâ€“reperfusion injury after unilateral lung transplantation. Intensive Care Medicine Experimental, 2021, 9, 4.	0.9	5
28	Discovery of 3-phenyl- and 3-N-piperidinyl-isothiazolo[4,3-b]pyridines as highly potent inhibitors of cyclin G-associated kinase. European Journal of Medicinal Chemistry, 2021, 213, 113158.	2.6	10
29	Small Molecule Cyclotriazadisulfonamide Abrogates the Upregulation of the Human Receptors CD4 and 4-1BB and Suppresses In Vitro Activation and Proliferation of T Lymphocytes. Frontiers in Immunology, 2021, 12, 650731.	2.2	6
30	A patent review of adaptor associated kinase 1 (AAK1) inhibitors (2013-present). Expert Opinion on Therapeutic Patents, 2021, 31, 911-936.	2.4	15
31	Active Components from Cassia abbreviata Prevent HIV-1 Entry by Distinct Mechanisms of Action. International Journal of Molecular Sciences, 2021, 22, 5052.	1.8	6
32	Biological characterization of ligands targeting the human CC chemokine receptor 8 (CCR8) reveals the biased signaling properties of small molecule agonists. Biochemical Pharmacology, 2021, 188, 114565.	2.0	7
33	Synthesis, molecular docking, and preliminary cytotoxicity study of some novel 2-(naphthalen-1-yl)-methylimidazo[2,1-b][1,3,4]thiadiazoles. Journal of Molecular Structure, 2021, 1234, 130174.	1.8	2
34	Multivalent Tryptophanâ€and Tyrosineâ€Containing [60]Fullerene Hexaâ€Adducts as Dual HIV and Enterovirus A71 Entry Inhibitors. Chemistry - A European Journal, 2021, 27, 10700-10710.	1.7	9
35	A Novel Series of Indole Alkaloid Derivatives Inhibit Dengue and Zika Virus Infection by Interference with the Viral Replication Complex. Antimicrobial Agents and Chemotherapy, 2021, 65, e0234920.	1.4	13
36	Novel N-Substituted 3-Aryl-4-(diethoxyphosphoryl)azetidin-2-ones as Antibiotic Enhancers and Antiviral Agents in Search for a Successful Treatment of Complex Infections. International Journal of Molecular Sciences, 2021, 22, 8032.	1.8	5

#	Article	IF	Citations
37	Double Arylation of the Indole Side Chain of Tri- and Tetrapodal Tryptophan Derivatives Renders Highly Potent HIV-1 and EV-A71 Entry Inhibitors. Journal of Medicinal Chemistry, 2021, 64, 10027-10046.	2.9	7
38	Water-Promoted Reaction of C₆₀Ar₅Cl Compounds with Thiophenes Delivers a Family of Multifunctional Fullerene Derivatives with Selective Antiviral Properties. Organic Letters, 2021, 23, 7226-7230.	2.4	7
39	Broad spectrum anti-coronavirus activity of a series of anti-malaria quinoline analogues. Antiviral Research, 2021, 193, 105127.	1.9	27
40	Labyrinthopeptin A1 inhibits dengue and Zika virus infection by interfering with the viral phospholipid membrane. Virology, 2021, 562, 74-86.	1.1	12
41	Thiophene-2-carboxamide derivatives of anthraquinone: A new potent antitumor chemotype. European Journal of Medicinal Chemistry, 2021, 221, 113521.	2.6	12
42	Exploring the dNTP -binding site of HIV-1 reverse transcriptase for inhibitor design. European Journal of Medicinal Chemistry, 2021, 225, 113785.	2.6	3
43	Synthesis, Molecular Docking and Molecular Dynamics Simulation of 2- Thioxothiazolidin-4-One Derivatives against Gp41. Current HIV Research, 2021, 19, 47-60.	0.2	2
44	A Proteomic Study on the Membrane Protein Fraction of T Cells Confirms High Substrate Selectivity for the ER Translocation Inhibitor Cyclotriazadisulfonamide. Molecular and Cellular Proteomics, 2021, 20, 100144.	2.5	7
45	A single-dose live-attenuated YF17D-vectored SARS-CoV-2 vaccine candidate. Nature, 2021, 590, 320-325.	13.7	148
46	D-Peptide-Based Probe for CXCR4-Targeted Molecular Imaging and Radionuclide Therapy. Pharmaceutics, 2021, 13, 1619.	2.0	5
47	Synthesis and Anti-HIV Activity of a Novel Series of Isoquinoline-Based CXCR4 Antagonists. Molecules, 2021, 26, 6297.	1.7	2
48	Peripherally-driven myeloid NFkB and IFN/ISG responses predict malignancy risk, survival, and immunotherapy regime in ovarian cancer. , 2021, 9, e003609.		24
49	Skeleton binding protein-1-mediated parasite sequestration inhibits spontaneous resolution of malaria-associated acute respiratory distress syndrome. PLoS Pathogens, 2021, 17, e1010114.	2.1	7
50	Deciphering the Role of Extracellular Vesicles Derived from ZIKV-Infected hcMEC/D3 Cells on the Bloodâ€“Brain Barrier System. Viruses, 2021, 13, 2363.	1.5	8
51	Neo-Adjuvant Chemotherapy Reduces, and Surgery Increases Immunosuppression in First-Line Treatment for Ovarian Cancer. Cancers, 2021, 13, 5899.	1.7	9
52	Sliding of HIV-1 reverse transcriptase over DNA creates a transient P pocket â€“ targeting P-pocket by fragment screening. Nature Communications, 2021, 12, 7127.	5.8	6
53	⁶⁴Cu PET Imaging of the CXCR4 Chemokine Receptor Using a Cross-Bridged Cyclam Bis-Tetraazamacrocyclic Antagonist. Journal of Nuclear Medicine, 2020, 61, 123-128.	2.8	18
54	Design, synthesis and antiviral evaluation of novel acyclic phosphonate nucleotide analogs with triazolo[4,5-b]pyridine, imidazo[4,5-b]pyridine and imidazo[4,5-b]pyridin-2(3H)-one systems. Nucleosides, Nucleotides and Nucleic Acids, 2020, 39, 542-591.	0.4	8

#	Article	IF	Citations
55	Synthesis, characterization and anti-HIV activity of polycarboxylic [60]fullerene derivatives obtained in the reaction of C60Cl6 with a hydroquinone ether. Tetrahedron Letters, 2020, 61, 151598.	0.7	11
56	Direct arylation of C₆₀Cl₆ and C₇₀Cl₈ with carboxylic acids: a synthetic avenue to water-soluble fullerene derivatives with promising antiviral activity. Chemical Communications, 2020, 56, 1179-1182.	2.2	23
57	Labyrinthopeptins Exert Broad-Spectrum Antiviral Activity through Lipid-Binding-Mediated Virolysis. Journal of Virology, 2020, 94, .	1.5	30
58	Scaffold Simplification Strategy Leads to a Novel Generation of Dual Human Immunodeficiency Virus and Enterovirus-A71 Entry Inhibitors. Journal of Medicinal Chemistry, 2020, 63, 349-368.	2.9	20
59	Preprotein signature for full susceptibility to the coâ€translational translocation inhibitor cyclotriazadisulfonamide. Traffic, 2020, 21, 250-264.	1.3	12
60	Assessment of protein biomarkers for preoperative differential diagnosis between benign and malignant ovarian tumors. Gynecologic Oncology, 2020, 159, 811-819.	0.6	8
61	Synthesis of new riboflavin modified ODNs: Effect of riboflavin moiety on the G-quadruplex arrangement and stability. Bioorganic Chemistry, 2020, 104, 104213.	2.0	0
62	Discovery of HIV entry inhibitors via a hybrid CXCR4 and CCR5 receptor pharmacophoreâ€based virtual screening approach. European Journal of Pharmaceutical Sciences, 2020, 155, 105537.	1.9	22
63	Membrane Permeable, Bioreversibly Modified Prodrugs of Nucleoside Diphosphate-Î³-Phosphonates. Journal of Medicinal Chemistry, 2020, 63, 11990-12007.	2.9	15
64	Thiophene-based water-soluble fullerene derivatives as highly potent antiherpetic pharmaceuticals. Organic and Biomolecular Chemistry, 2020, 18, 8702-8708.	1.5	4
65	Alkylated benzimidazoles: Design, synthesis, docking, DFT analysis, ADMET property, molecular dynamics and activity against HIV and YFV. Computational Biology and Chemistry, 2020, 89, 107400.	1.1	22
66	STAT2 signaling restricts viral dissemination but drives severe pneumonia in SARS-CoV-2 infected hamsters. Nature Communications, 2020, 11, 5838.	5.8	225
67	Î³-Ketobenzyl-Modified Nucleoside Triphosphate Prodrugs as Potential Antivirals. Journal of Medicinal Chemistry, 2020, 63, 13745-13761.	2.9	10
68	Water-soluble fullerene-based nanostructures with promising antiviral and myogenic activity. Chemical Communications, 2020, 56, 10203-10206.	2.2	13
69	Development of a Novel SPR Assay to Study CXCR4â€“Ligand Interactions. Biosensors, 2020, 10, 150.	2.3	8
70	Anti-HIV-Active Nucleoside Triphosphate Prodrugs. Journal of Medicinal Chemistry, 2020, 63, 6003-6027.	2.9	28
71	Prodrugs of Î³â€Alkylâ€Modified Nucleoside Triphosphates: Improved Inhibition of HIV Reverse Transcriptase. Angewandte Chemie - International Edition, 2020, 59, 22063-22071.	7.2	19
72	Prodrugs of Î³â€Alkylâ€Modified Nucleoside Triphosphates: Improved Inhibition of HIV Reverse Transcriptase. Angewandte Chemie, 2020, 132, 22247-22255.	1.6	0

#	Article	IF	Citations
73	Lipophilic Triphosphate Prodrugs of Various Nucleoside Analogues. Journal of Medicinal Chemistry, 2020, 63, 6991-7007.	2.9	14
74	A chimeric yellow fever-Zika virus vaccine candidate fully protects against yellow fever virus infection in mice. Emerging Microbes and Infections, 2020, 9, 520-533.	3.0	21
75	Synthesis of 2-[(ï‰-phthalimidoalkyl)sulfanyl]- pyrimidin-4(3H)-ones, their cytotoxicity and in vitro activity against HIV-1/2. Chemistry of Heterocyclic Compounds, 2020, 56, 67-72.	0.6	5
76	Design, synthesis and biological evaluation of 2-alkoxycarbonyl-3-anilinoindoles as a new class of potent inhibitors of tubulin polymerization. Bioorganic Chemistry, 2020, 97, 103665.	2.0	16
77	Early protein expression profile in bronchoalveolar lavage fluid and clinical outcomes in primary graft dysfunction after lung transplantation. European Journal of Cardio-thoracic Surgery, 2020, 58, 379-388.	0.6	4
78	Tryptophan Trimers and Tetramers Inhibit Dengue and Zika Virus Replication by Interfering with Viral Attachment Processes. Antimicrobial Agents and Chemotherapy, 2020, 64, .	1.4	8
79	Amides of pyrrole- and thiophene-fused anthraquinone derivatives: A role of the heterocyclic core in antitumor properties. European Journal of Medicinal Chemistry, 2020, 199, 112294.	2.6	22
80	Design, Synthesis, and Biological Evaluation of Novel C5-Modified Pyrimidine Ribofuranonucleosides as Potential Antitumor or/and Antiviral Agents. Medicinal Chemistry, 2020, 16, 368-384.	0.7	6
81	Synthesis and Evaluations of â€œ1,4â€Triazolyl Combretacoumarinsâ€•and Desmethoxy Analogs. European Journal of Organic Chemistry, 2019, 2019, 5610-5623.	1.2	7
82	A unique class of lignin derivatives displays broad anti-HIV activity by interacting with the viral envelope. Virus Research, 2019, 274, 197760.	1.1	10
83	Novel Isoxazolidine and Î³-Lactam Analogues of Homonucleosides. Molecules, 2019, 24, 4014.	1.7	14
84	Antitumor and antiviral activities of 4-substituted 1,2,3-triazolyl-2,3-dibenzyl-L-ascorbic acid derivatives. European Journal of Medicinal Chemistry, 2019, 184, 111739.	2.6	25
85	Acetate as a model for aspartate-based CXCR4 chemokine receptor binding of cobalt and nickel complexes of cross-bridged tetraazamacrocycles. Dalton Transactions, 2019, 48, 2785-2801.	1.6	11
86	Modifications in the branched arms of a class of dual inhibitors of HIV and EV71 replication expand their antiviral spectrum. Antiviral Research, 2019, 168, 210-214.	1.9	9
87	Diversion of the Arbuzov reaction: alkylation of Câ€“Cl instead of phosphonic ester formation on the fullerene cage. Organic and Biomolecular Chemistry, 2019, 17, 7155-7160.	1.5	12
88	Advantages and shortcomings of cell-based electrical impedance measurements as a GPCR drug discovery tool. Biosensors and Bioelectronics, 2019, 137, 33-44.	5.3	20
89	Acyclic nucleoside phosphonates containing the amide bond: hydroxy derivatives. Monatshefte FÃ¼r Chemie, 2019, 150, 733-745.	0.9	2
90	Prone Positioning During ExÂVivo Lung Perfusion Influences Regional Edema Accumulation. Journal of Surgical Research, 2019, 239, 300-308.	0.8	24

#	Article	IF	Citations
91	Highly stable hexitol based XNA aptamers targeting the vascular endothelial growth factor. Nucleic Acids Research, 2019, 47, 4927-4939.	6.5	73
92	Synthesis and Anti-HIV Activity of Guanine Modified Fluorinated Acyclic Nucleoside Phosphonate Derivatives. Chemistry and Biodiversity, 2019, 16, e1800532.	1.0	3
93	Synthesis, Anti-Varicella-Zoster Virus and Anti-Cytomegalovirus Activity of 4,5-Disubstituted 1,2,3-(1H)-Triazoles. Medicinal Chemistry, 2019, 15, 801-812.	0.7	7
94	CXCR7/ACKR3-targeting ligands interfere with X7 HIV-1 and HIV-2 entry and replication in human host cells. Heliyon, 2018, 4, e00557.	1.4	10
95	Synthesis of Enantiomerically Pure 1â€²,2â€²-cis-dideoxy, -dideoxydiÂdehydro, -ribo and -deoxy Carbocyclic Nucleoside Analogues. Synthesis, 2018, 50, 2266-2280.	1.2	4
96	New antitumor anthra[2,3-b]furan-3-carboxamides: Synthesis and structure-activity relationship. European Journal of Medicinal Chemistry, 2018, 148, 128-139.	2.6	26
97	Different contributions of chemokine Nâ€terminal features attest to a different ligand binding mode and a bias towards activation of ACKR3/CXCR7 compared with CXCR4 and CXCR3. British Journal of Pharmacology, 2018, 175, 1419-1438.	2.7	52
98	A Flow Cytometry-based Assay to Identify Compounds That Disrupt Binding of Fluorescently-labeled CXC Chemokine Ligand 12 to CXC Chemokine Receptor 4. Journal of Visualized Experiments, 2018, , .	0.2	11
99	Aminomethylation of heliomycin: Preparation and anticancer characterization of the first series of semi-synthetic derivatives. European Journal of Medicinal Chemistry, 2018, 143, 1553-1562.	2.6	13
100	A yellow feverâ€“Zika chimeric virus vaccine candidate protects against Zika infection and congenital malformations in mice. Npj Vaccines, 2018, 3, 56.	2.9	41
101	Peroxynitrite Exposure of CXCL12 Impairs Monocyte, Lymphocyte and Endothelial Cell Chemotaxis, Lymphocyte Extravasation in vivo and Anti-HIV-1 Activity. Frontiers in Immunology, 2018, 9, 1933.	2.2	5
102	Tri-armed ligands of G-quadruplex on heteroarene-fused anthraquinone scaffolds: Design, synthesis and pre-screening of biological properties. European Journal of Medicinal Chemistry, 2018, 159, 59-73.	2.6	20
103	CXCR4-targeting nanobodies differentially inhibit CXCR4 function and HIV entry. Biochemical Pharmacology, 2018, 158, 402-412.	2.0	34
104	Nanobody-Fc constructs targeting chemokine receptor CXCR4 potently inhibit signaling and CXCR4-mediated HIV-entry and induce antibody effector functions. Biochemical Pharmacology, 2018, 158, 413-424.	2.0	44
105	Isoxazolidine Conjugates of N3-Substituted 6-Bromoquinazolinonesâ€”Synthesis, Anti-Varizella-Zoster Virus, and Anti-Cytomegalovirus Activity. Molecules, 2018, 23, 1889.	1.7	10
106	Synthesis and Antiviral Activity of Water-Soluble Polycarboxylic Derivatives of [60]Fullerene Loaded with 3,4-Dichlorophenyl Units. Chemistry and Biodiversity, 2018, 15, e1800293.	1.0	7
107	A Kinetic Fluorescence-based Ca²⁺ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators. Journal of Visualized Experiments, 2018, , .	0.2	5
108	Expedient synthesis and biological evaluation of alkenyl acyclic nucleoside phosphonate prodrugs. Bioorganic and Medicinal Chemistry, 2018, 26, 3596-3609.	1.4	4

#	Article	IF	Citations
109	Synthesis and Antiviral Evaluation of TriPPProâ€AbacavirTP, TriPPProâ€CarbovirTP, and Their 1â€²,2â€²â€cisâ€Disubstituted Analogues. ChemMedChem, 2018, 13, 1771-1778.	1.6	8
110	Asymmetric Primaquine and Halogenaniline Fumardiamides as Novel Biologically Active Michael Acceptors. Molecules, 2018, 23, 1724.	1.7	8
111	Synthesis of a 3â€²-C-ethynyl-Î²-d-ribofuranose purine nucleoside library: Discovery of C7-deazapurine analogs as potent antiproliferative nucleosides. European Journal of Medicinal Chemistry, 2018, 157, 248-267.	2.6	15
112	Engineering Lactobacillus rhamnosus GG and GR-1 to express HIV-inhibiting griffithsin. International Journal of Antimicrobial Agents, 2018, 52, 599-607.	1.1	18
113	Iterative Chemical Engineering of Vancomycin Leads to Novel Vancomycin Analogs With a High in Vitro Therapeutic Index. Frontiers in Microbiology, 2018, 9, 1175.	1.5	9
114	Chloro-1,4-dimethyl-9H-carbazole Derivatives Displaying Anti-HIV Activity. Molecules, 2018, 23, 286.	1.7	15
115	Polyfunctionalized Pyrrole Derivatives: Easy Three-component Microwave-assisted Synthesis, Cytostatic and Antiviral Evaluation. Current Microwave Chemistry, 2018, 5, 23-31.	0.2	8
116	Design, synthesis, in vitro antiproliferative activity and apoptosis-inducing studies of 1-(3â€²,4â€²,5â€²-trimethoxyphenyl)-3-(2â€²-alkoxycarbonylindolyl)-2-propen-1-one derivatives obtained by a molecular hybridisation approach. Journal of Enzyme Inhibition and Medicinal Chemistry, 2018, 33, 1225-1238.	2.5	16
117	Facile Microwave-assisted Synthesis of Various C5-modified Pyrimidine Pyranonucleosides as Potential Cytotoxic Antitumor Agents. Current Microwave Chemistry, 2018, 4, .	0.2	1
118	A Proteomic Survey Indicates Sortilin as a Secondary Substrate of the ER Translocation Inhibitor Cyclotriazadisulfonamide (CADA). Molecular and Cellular Proteomics, 2017, 16, 157-167.	2.5	17
119	Structure-activity relationship studies on a Trp dendrimer with dual activities against HIV and enterovirus A71. Modifications on the amino acid. Antiviral Research, 2017, 139, 32-40.	1.9	17
120	Facile functionalization at the C4 position of pyrimidine nucleosides via amide group activation with (benzotriazol-1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate (BOP) and biological evaluations of the products. Organic and Biomolecular Chemistry, 2017, 15, 1130-1139.	1.5	17
121	Design, Synthesis, and the Biological Evaluation of a New Series of Acyclic 1,2,3â€Triazole Nucleosides. Archiv Der Pharmazie, 2017, 350, 1700166.	2.1	8
122	Expanding the Antiviral Spectrum of 3-Fluoro-2-(phosphonomethoxy)propyl Acyclic Nucleoside Phosphonates: Diamyl Aspartate Amidate Prodrugs. Journal of Medicinal Chemistry, 2017, 60, 6220-6238.	2.9	22
123	Synthesis of different types of alkoxy fullerene derivatives from chlorofullerene C₆₀Cl₆. Organic and Biomolecular Chemistry, 2017, 15, 773-777.	1.5	28
124	Synthesis, anti-varicella-zoster virus and anti-cytomegalovirus activity of quinazoline-2,4-diones containing isoxazolidine and phosphonate substructures. European Journal of Medicinal Chemistry, 2017, 126, 84-100.	2.6	27
125	Signaling properties of the human chemokine receptors CXCR4 and CXCR7 by cellular electric impedance measurements. PLoS ONE, 2017, 12, e0185354.	1.1	21
126	Comparison of cell-based assays for the identification and evaluation of competitive CXCR4 inhibitors. PLoS ONE, 2017, 12, e0176057.	1.1	33

#	Article	IF	Citations
127	Immunoregulatory effects of multipotent adult progenitor cells in a porcine ex vivo lung perfusion model. Stem Cell Research and Therapy, 2017, 8, 159.	2.4	51
128	Synthesis and Ativiral Activity of 5-(Benzylthio)-4-carbamyl-1,2,3-triazoles Against Human Cytomegalovirus (CMV) and Varicella-zoster Virus (VZV). Medicinal Chemistry, 2017, 13, 453-464.	0.7	9
129	A porcine ex vivo lung perfusion model with maximal argon exposure to attenuate ischemia-reperfusion injury. Medical Gas Research, 2017, 7, 28.	1.2	8
130	New Isoxazolidine-Conjugates of Quinazolinonesâ€"Synthesis, Antiviral and Cytostatic Activity. Molecules, 2016, 21, 959.	1.7	19
131	Design, Synthesis and Biological Evaluation of Novel Primaquine-Cinnamic Acid Conjugates of the Amide and Acylsemicarbazide Type. Molecules, 2016, 21, 1629.	1.7	22
132	Development and Identification of a Novel Anti-HIV-1 Peptide Derived by Modification of the N-Terminal Domain of HIV-1 Integrase. Frontiers in Microbiology, 2016, 7, 845.	1.5	13
133	Synthesis and the Biological Activity of Phosphonylated 1,2,3-Triazolenaphthalimide Conjugates. Molecules, 2016, 21, 1420.	1.7	12
134	Lectin-Like Molecules of Lactobacillus rhamnosus GG Inhibit Pathogenic Escherichia coli and Salmonella Biofilm Formation. PLoS ONE, 2016, 11, e0161337.	1.1	79
135	Membraneâ€permeable Triphosphate Prodrugs of Nucleoside Analogues. Angewandte Chemie - International Edition, 2016, 55, 5255-5258.	7.2	57
136	The lectin-like protein 1 in Lactobacillus rhamnosus GR-1 mediates tissue-specific adherence to vaginal epithelium and inhibits urogenital pathogens. Scientific Reports, 2016, 6, 37437.	1.6	38
137	Synthesis of novel N-acyl-Î²-d-glucopyranosylamines and ureas as potential lead cytostatic agents. Medicinal Chemistry Research, 2016, 25, 932-940.	1.1	1
138	Novel urea and bis -urea primaquine derivatives with hydroxyphenyl or halogenphenyl substituents: Synthesis and biological evaluation. European Journal of Medicinal Chemistry, 2016, 124, 622-636.	2.6	27
139	Steroids can reduce warm ischemic reperfusion injury in a porcine donation after circulatory death model withex vivolung perfusion evaluation. Transplant International, 2016, 29, 1237-1246.	0.8	42
140	Synthesis and antiviral properties of new derivatives of 2-(alkylsulfanyl)-6-[1-(2,6-difluorophenyl)cyclopropyl]-5-methylpyrimidin-4(3H)-one. Russian Journal of Organic Chemistry, 2016, 52, 1188-1193.	0.3	3
141	Lectin-Glycan Interaction Network-Based Identification of Host Receptors of Microbial Pathogenic Adhesins. MBio, 2016, 7, .	1.8	48
142	Design, Synthesis, and Antiviral Activity of Novel Ribonucleosides of 1,2,3â€Triazolylbenzylâ€aminophosphonates. Archiv Der Pharmazie, 2016, 349, 30-41.	2.1	30
143	Design, synthesis, and cytostatic activity of novel pyrazine sorafenib analogs. Medicinal Chemistry Research, 2016, 25, 2729-2741.	1.1	7
144	Humoral immunity in phenotypes of chronic lung allograft dysfunction: A broncho-alveolar lavage fluid analysis. Transplant Immunology, 2016, 38, 27-32.	0.6	36

#	Article	IF	Citations
145	Aspartateâ€Based CXCR4 Chemokine Receptor Binding of Crossâ€Bridged Tetraazamacrocyclic Copper(II) and Zinc(II) Complexes. Chemistry - A European Journal, 2016, 22, 12916-12930.	1.7	16
146	High mannose-specific lectin Msl mediates key interactions of the vaginal Lactobacillus plantarum isolate CMPG5300. Scientific Reports, 2016, 6, 37339.	1.6	29
147	Novel isoxazolidine analogues of homonucleosides and homonucleotides. Tetrahedron, 2016, 72, 8294-8308.	1.0	9
148	Acyclic nucleoside phosphonates containing the amide bond. Monatshefte FÃ¼r Chemie, 2016, 147, 2163-2177.	0.9	2
149	Synthesis of Novel Chiral Sulfonamideâ€Bearing 1,2,4â€Triazoleâ€3â€thione Analogs Derived from Dâ€ and Lâ€Phenylalanine Esters as Potential Antiâ€Influenza Agents. Chirality, 2016, 28, 495-513.	1.3	22
150	Synthesis, antiviral, cytotoxic and cytostatic evaluation of N 1-(phosphonoalkyl)uracil derivatives. Monatshefte FÃ¼r Chemie, 2016, 147, 1081-1090.	0.9	3
151	Membraneâ€permeable Triphosphate Prodrugs of Nucleoside Analogues. Angewandte Chemie, 2016, 128, 5341-5344.	1.6	12
152	Vascular endothelial growth factor pathway in endometriosis: genetic variants and plasma biomarkers. Fertility and Sterility, 2016, 105, 988-996.	0.5	36
153	Tuning Side Arm Electronics in Unsymmetrical Cyclotriazadisulfonamide (CADA) Endoplasmic Reticulum (ER) Translocation Inhibitors to Improve their Human Cluster of Differentiation 4 (CD4) Receptor Down-Modulating Potencies. Journal of Medicinal Chemistry, 2016, 59, 2633-2647.	2.9	16
154	Exploring the purine core of 3â€²-C-ethynyladenosine (EAdo) in search of novel nucleoside therapeutics. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 1970-1972.	1.0	6
155	Discovery of antitumor anthra[2,3-b]furan-3-carboxamides: Optimization of synthesis and evaluation of antitumor properties. European Journal of Medicinal Chemistry, 2016, 112, 114-129.	2.6	48
156	Synthesis and Bioactivity of Novel Trisubstituted Triazole Nucleosides. Nucleosides, Nucleotides and Nucleic Acids, 2016, 35, 147-160.	0.4	7
157	The Viral Polymerase Inhibitor 7-Deaza-2â€™-C-Methyladenosine Is a Potent Inhibitor of In Vitro Zika Virus Replication and Delays Disease Progression in a Robust Mouse Infection Model. PLoS Neglected Tropical Diseases, 2016, 10, e0004695.	1.3	250
158	4-(1-Adamantyl)phenylalkylamines with Potential Antiproliferative Activity. Letters in Organic Chemistry, 2016, 13, 171-176.	0.2	11
159	SYNTHESIS OF IMIDAZO[2,1-b][1,3,4]THIADIAZOLE DERIVATIVES AS POSSIBLE BIOLOGICALLY ACTIVE AGENTS. Acta Poloniae Pharmaceutica, 2016, 73, 913-929.	0.3	2
160	SYNTHESIS AND PHARMACOLOGICAL ACTIVITY OF IMIDAZO[2,1- b][1,3,4]THIADIAZOLE DERIVATIVES. Acta Poloniae Pharmaceutica, 2016, 73, 937-947.	0.3	1
161	Study of the Chemoselectivity of Multicomponent Heterocyclizations Involving 3â€Aminoâ€1,2,4â€triazole and Pyruvic Acids as Key Reagents, and Biological Activity of the Reaction Products. European Journal of Organic Chemistry, 2015, 2015, 4481-4492.	1.2	33
162	An easy microwave-assisted synthesis of C8-alkynyl adenine pyranonucleosides as novel cytotoxic antitumor agents. Frontiers in Chemistry, 2015, 3, 21.	1.8	7

#	Article	IF	Citations
163	Phosphonylated Acyclic Guanosine Analogues with the 1,2,3-Triazole Linker. Molecules, 2015, 20, 18789-18807.	1.7	8
164	Differential Cytokine, Chemokine and Growth Factor Expression in Phenotypes of Chronic Lung Allograft Dysfunction. Transplantation, 2015, 99, 86-93.	0.5	57
165	Phosphonylated 8-Azahypoxantines as Acyclic Nucleotide Analogs. Phosphorus, Sulfur and Silicon and the Related Elements, 2015, 190, 2207-2221.	0.8	3
166	Structural analogs of umifenovir 2*. The synthesis and antiHIV activity study of new regioisomeric (trans-2-phenylcyclopropyl)-1Ð•indole derivatives. Chemistry of Heterocyclic Compounds, 2015, 51, 978-983.	0.6	11
167	New AMD3100 derivatives for CXCR4 chemokine receptor targeted molecular imaging studies: synthesis, anti-HIV-1 evaluation and binding affinities. Dalton Transactions, 2015, 44, 5004-5016.	1.6	28
168	Diastereoselective Synthesis of (1,3â€Ðioxanâ€4â€yl)pyrimidine and Purin Nucleoside Analogues. European Journal of Organic Chemistry, 2015, 2015, 1235-1245.	1.2	4
169	NICTABA and UDA, two GlcNAc-binding lectins with unique antiviral activity profiles. Journal of Antimicrobial Chemotherapy, 2015, 70, 1674-1685.	1.3	32
170	BAL neutrophilia in azithromycin-treated lung transplant recipients: Clinical significance. Transplant Immunology, 2015, 33, 37-44.	0.6	14
171	Nucleoside Diphosphate Prodrugs: Nonsymmetric DiPPro-Nucleotides. Journal of Medicinal Chemistry, 2015, 58, 6114-6130.	2.9	47
172	The Role of B-Cells in Phenotypes of Chronic Lung Allograft Dysfunction. Journal of Heart and Lung Transplantation, 2015, 34, S29.	0.3	1
173	Branched-chain sugar nucleosides: stereocontrolled synthesis and bioevaluation of novel 3â€²-C-trifluoromethyl and 3â€²-C-methyl pyranonucleosides. Carbohydrate Research, 2015, 407, 170-178.	1.1	2
174	Synthesis and evaluation of the biological activity of Nâ€²-[2-oxo-1,2 dihydro-3H-indol-3-ylidene] benzohydrazides as potential anticancer agents. RSC Advances, 2015, 5, 45492-45501.	1.7	21
175	Design, antiviral and cytostatic properties of isoxazolidine-containing amonafide analogues. Bioorganic and Medicinal Chemistry, 2015, 23, 3135-3146.	1.4	26
176	Synthesis of Novel Thiopurine Pyranonucleosides: Evaluation of Their Bioactivity. Nucleosides, Nucleotides and Nucleic Acids, 2015, 34, 289-308.	0.4	3
177	Bis(benzoyloxybenzyl)â€DiPPro Nucleoside Diphosphates of Antiâ€HIV Active Nucleoside Analogues. ChemMedChem, 2015, 10, 891-900.	1.6	13
178	Lipophilic prodrugs of nucleoside triphosphates as biochemical probes and potential antivirals. Nature Communications, 2015, 6, 8716.	5.8	65
179	Engineering a Therapeutic Lectin by Uncoupling Mitogenicity from Antiviral Activity. Cell, 2015, 163, 746-758.	13.5	89
180	An efficient one-pot conversion of Boc-protected adenines to N6-ureas. Tetrahedron Letters, 2015, 56, 6574-6576.	0.7	3

#	Article	IF	Citations
181	Metal complexes of pyridine-fused macrocyclic polyamines targeting the chemokine receptor CXCR4. Organic and Biomolecular Chemistry, 2015, 13, 10517-10526.	1.5	6
182	Novel halogenated 3-deazapurine, 7-deazapurine and alkylated 9-deazapurine derivatives of l-ascorbic or imino-l-ascorbic acid: Synthesis, antitumour and antiviral activity evaluations. European Journal of Medicinal Chemistry, 2015, 102, 288-302.	2.6	13
183	The Low-Cost Compound Lignosulfonic Acid (LA) Exhibits Broad-Spectrum Anti-HIV and Anti-HSV Activity and Has Potential for Microbicidal Applications. PLoS ONE, 2015, 10, e0131219.	1.1	47
184	HIV-1 and Its Resistance to Peptidic Carbohydrate-Binding Agents (CBAs): An Overview. Molecules, 2014, 19, 21085-21112.	1.7	6
185	Signal Peptide-Binding Drug as a Selective Inhibitor of Co-Translational Protein Translocation. PLoS Biology, 2014, 12, e1002011.	2.6	39
186	Azithromycin and the Treatment of Lymphocytic Airway Inflammation After Lung Transplantation. American Journal of Transplantation, 2014, 14, 2736-2748.	2.6	34
187	Indolylarylsulfones Carrying a Heterocyclic Tail as Very Potent and Broad Spectrum HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors. Journal of Medicinal Chemistry, 2014, 57, 9945-9957.	2.9	42
188	Combination of the CCL5-Derived Peptide R4.0 with Different HIV-1 Blockers Reveals Wide Target Compatibility and Synergic Cobinding to CCR5. Antimicrobial Agents and Chemotherapy, 2014, 58, 6215-6223.	1.4	6
189	2-(4-Chlorobenzyl)-6-arylimidazo[2,1-b][1,3,4]thiadiazoles: Synthesis, cytotoxic activity and mechanism of action. European Journal of Medicinal Chemistry, 2014, 84, 687-697.	2.6	26
190	Novel semicarbazides and ureas of primaquine with bulky aryl or hydroxyalkyl substituents: Synthesis, cytostatic and antioxidative activity. European Journal of Medicinal Chemistry, 2014, 86, 502-514.	2.6	28
191	Broad anti-HIV activity of the Oscillatoria agardhii agglutinin homologue lectin family. Journal of Antimicrobial Chemotherapy, 2014, 69, 2746-2758.	1.3	39
192	Design, synthesis, antiviral and cytostatic activity of Ï‰-(1H-1,2,3-triazol-1-yl)(polyhydroxy)alkylphosphonates as acyclic nucleotide analogues. Bioorganic and Medicinal Chemistry, 2014, 22, 3629-3641.	1.4	30
193	229. Cytokine, 2013, 63, 297.	1.4	0
194	Design of Substituted Imidazolidinylpiperidinylbenzoic Acids as Chemokine Receptor 5 Antagonists: Potent Inhibitors of R5 HIV-1 Replication. Journal of Medicinal Chemistry, 2013, 56, 8049-8065.	2.9	8
195	A Multi-targeted Drug Candidate with Dual Anti-HIV and Anti-HSV Activity. PLoS Pathogens, 2013, 9, e1003456.	2.1	16
196	Sulfated Escherichia coli K5 Polysaccharide Derivatives Inhibit Dengue Virus Infection of Human Microvascular Endothelial Cells by Interacting with the Viral Envelope Protein E Domain III. PLoS ONE, 2013, 8, e74035.	1.1	35
197	The Lantibiotic Peptide Labyrinthopeptin A1 Demonstrates Broad Anti-HIV and Anti-HSV Activity with Potential for Microbicidal Applications. PLoS ONE, 2013, 8, e64010.	1.1	123
198	Combination of Antiretroviral Drugs as Microbicides. Current HIV Research, 2012, 10, 53-60.	0.2	10

#	Article	IF	Citations
199	Improving potencies and properties of CD4 down-modulating CADA analogs. Expert Opinion on Drug Discovery, 2012, 7, 39-48.	2.5	6
200	Combinations of Griffithsin with Other Carbohydrate-Binding Agents Demonstrate Superior Activity Against HIV Type 1, HIV Type 2, and Selected Carbohydrate-Binding Agent-Resistant HIV Type 1 Strains. AIDS Research and Human Retroviruses, 2012, 28, 1513-1523.	0.5	39
201	A Short Hairpin Loop-Structured Oligodeoxynucleotide Targeting the Virion-Associated RNase H of HIV Inhibits HIV Production in Cell Culture and in huPBL-SCID Mice. Intervirology, 2012, 55, 242-246.	1.2	6
202	Dengue Virus Entry as Target for Antiviral Therapy. Journal of Tropical Medicine, 2012, 2012, 1-13.	0.6	45
203	Feglymycin, a unique natural bacterial antibiotic peptide, inhibits HIV entry by targeting the viral envelope protein gp120. Virology, 2012, 433, 308-319.	1.1	19
204	CXCR4 chemokine receptor antagonists: nickel(ii) complexes of configurationally restricted macrocycles. Dalton Transactions, 2012, 41, 11369.	1.6	35
205	Mitigating hERG Inhibition: Design of Orally Bioavailable CCR5 Antagonists as Potent Inhibitors of R5 HIV-1 Replication. ACS Medicinal Chemistry Letters, 2012, 3, 216-221.	1.3	6
206	Thioredoxin-1 and protein disulfide isomerase catalyze the reduction of similar disulfides in HIV gp120. International Journal of Biochemistry and Cell Biology, 2012, 44, 556-562.	1.2	36
207	Crucial role of the N-glycans on the viral E-envelope glycoprotein in DC-SIGN-mediated dengue virus infection. Antiviral Research, 2012, 96, 280-287.	1.9	29
208	HIV-1 X4 Activities of Polycationic â€œViologenâ€•Based Dendrimers by Interaction with the Chemokine Receptor CXCR4: Study of Structureâ€“Activity Relationship. Journal of Medicinal Chemistry, 2012, 55, 10405-10413.	2.9	41
209	Algal Lectins as Potential HIV Microbicide Candidates. Marine Drugs, 2012, 10, 1476-1497.	2.2	74
210	Evaluation of a panel of 28 biomarkers for the non-invasive diagnosis of endometriosis. Human Reproduction, 2012, 27, 2698-2711.	0.4	152
211	New Nitrogen Containing Substituents at the Indole-2-carboxamide Yield High Potent and Broad Spectrum Indolylarylsulfone HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors. Journal of Medicinal Chemistry, 2012, 55, 6634-6638.	2.9	52
212	The molecular pharmacology of AMD11070: An orally bioavailable CXCR4 HIV entry inhibitor. Biochemical Pharmacology, 2012, 83, 472-479.	2.0	36
213	The orally bioavailable allosteric CXCR4 HIV-1 entry inhibitor AMD11070. Retrovirology, 2012, 9, .	0.9	1
214	Griffithsin, Alone and Combined with All Classes of Antiretroviral Drugs, Potently Inhibits HIV Cell-Cell Transmission and Destruction of CD4+ T cells. Journal of Antivirals & Antiretrovirals, 2012, 04, .	0.1	5
215	Indolylarylsulfones as HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors: New Cyclic Substituents at Indole-2-carboxamide. Journal of Medicinal Chemistry, 2011, 54, 1587-1598.	2.9	137
216	Targeting HIV Entry through Interaction with Envelope Glycoprotein 120 (gp120): Synthesis and Antiviral Evaluation of 1,3,5-Triazines with Aromatic Amino Acids. Journal of Medicinal Chemistry, 2011, 54, 5335-5348.	2.9	33

#	Article	IF	Citations
217	Unsymmetrical Cyclotriazadisulfonamide (CADA) Compounds as Human CD4 Receptor Down-Modulating Agents. Journal of Medicinal Chemistry, 2011, 54, 5712-5721.	2.9	16
218	Investigation of Griffithsin's Interactions with Human Cells Confirms Its Outstanding Safety and Efficacy Profile as a Microbicide Candidate. PLoS ONE, 2011, 6, e22635.	1.1	99
219	Virus-inhibitory peptide. Aids, 2011, 25, 1663-1664.	1.0	6
220	HIV-1 entry inhibition by small-molecule CCR5 antagonists: A combined molecular modeling and mutant study using a high-throughput assay. Virology, 2011, 413, 231-243.	1.1	25
221	Synergistic activity profile of griffithsin in combination with tenofovir, maraviroc and enfuvirtide against HIV-1 clade C. Virology, 2011, 417, 253-258.	1.1	49
222	Synergistic in vitro anti-HIV type 1 activity of tenofovir with carbohydrate-binding agents (CBAs). Antiviral Research, 2011, 90, 200-204.	1.9	17
223	Resistance to raltegravir highlights integrase mutations at codon 148 in conferring cross-resistance to a second-generation HIV-1 integrase inhibitor. Antiviral Research, 2011, 91, 167-176.	1.9	30
224	Early identification of availability issues for poorly water-soluble microbicide candidates in biorelevant media: A case study with saquinavir. Antiviral Research, 2011, 91, 217-223.	1.9	14
225	Design and synthesis of pyridin-2-ylmethylaminopiperidin-1-ylbutyl amide CCR5 antagonists that are potent inhibitors of M-tropic (R5) HIV-1 replication. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 6950-6954.	1.0	7
226	Prospective CCR5 Small Molecule Antagonist Compound Design Using a Combined Mutagenesis/Modeling Approach. Journal of the American Chemical Society, 2011, 133, 16477-16485.	6.6	17
227	Differences in the mannose oligomer specificities of the closely related lectins from Galanthus nivalis and Zea maysstrongly determine their eventual anti-HIV activity. Retrovirology, 2011, 8, 10.	0.9	24
228	Synergistic anti-HIV-1 activity of griffithsin with tenofovir, maraviroc and enfuvirtide. Retrovirology, 2011, 8, .	0.9	1
229	CXCR4 and CCR5 ligands cooperate in monocyte and lymphocyte migration and in inhibition of dualâ€tropic (R5/X4) HIVâ€1 infection. European Journal of Immunology, 2011, 41, 963-973.	1.6	64
230	Synthesis and SAR of novel CXCR4 antagonists that are potent inhibitors of T tropic (X4) HIV-1 replication. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 262-266.	1.0	30
231	Design of novel CXCR4 antagonists that are potent inhibitors of T-tropic (X4) HIV-1 replication. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 1414-1418.	1.0	20
232	Design and synthesis of pyridin-2-yloxymethylpiperidin-1-ylbutyl amide CCR5 antagonists that are potent inhibitors of M-tropic (R5) HIV-1 replication. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 2450-2455.	1.0	8
233	Agonist-Induced Internalization of CC Chemokine Receptor 5 as a Mechanism to Inhibit HIV Replication. Journal of Pharmacology and Experimental Therapeutics, 2011, 337, 655-662.	1.3	17
234	Broad Antiviral Activity of Carbohydrate-Binding Agents against the Four Serotypes of Dengue Virus in Monocyte-Derived Dendritic Cells. PLoS ONE, 2011, 6, e21658.	1.1	57

#	Article	IF	Citations
235	DC-SIGN Increases the Affinity of HIV-1 Envelope Glycoprotein Interaction with CD4. PLoS ONE, 2011, 6, e28307.	1.1	34
236	Primary mutations selected in vitro with raltegravir confer large fold changes in susceptibility to first-generation integrase inhibitors, but minor fold changes to inhibitors with second-generation resistance profiles. Virology, 2010, 402, 338-346.	1.1	58
237	PRO 2000, a broadly active anti-HIV sulfonated compound, inhibits viral entry by multiple mechanisms. Retrovirology, 2010, 7, .	0.9	1
238	Differential activity of candidate microbicides against early steps of HIV-1 infection upon complement virus opsonization. AIDS Research and Therapy, 2010, 7, 16.	0.7	6
239	Pradimicin S, a Highly Soluble Nonpeptidic Small-Size Carbohydrate-Binding Antibiotic, Is an Anti-HIV Drug Lead for both Microbicidal and Systemic Use. Antimicrobial Agents and Chemotherapy, 2010, 54, 1425-1435.	1.4	46
240	A Derivate of the Antibiotic Doxorubicin Is a Selective Inhibitor of Dengue and Yellow Fever Virus Replication In Vitro. Antimicrobial Agents and Chemotherapy, 2010, 54, 5269-5280.	1.4	72
241	Microvirin, a Novel Î±(1,2)-Mannose-specific Lectin Isolated from Microcystis aeruginosa, Has Anti-HIV-1 Activity Comparable with That of Cyanovirin-N but a Much Higher Safety Profile. Journal of Biological Chemistry, 2010, 285, 24845-24854.	1.6	108
242	A New Class of Dualâ€Targeted Antivirals: Monophosphorylated Acyclovir Prodrug Derivatives Suppress Both Human Immunodeficiency Virus Type 1 and Herpes Simplex Virus Type 2. Journal of Infectious Diseases, 2010, 201, 635-643.	1.9	33
243	CXCL12-CXCR4 Axis in Angiogenesis, Metastasis and Stem Cell Mobilization. Current Pharmaceutical Design, 2010, 16, 3903-3920.	0.9	193
244	Actinohivin, a Broadly Neutralizing Prokaryotic Lectin, Inhibits HIV-1 Infection by Specifically Targeting High-Mannose-Type Glycans on the gp120 Envelope. Antimicrobial Agents and Chemotherapy, 2010, 54, 3287-3301.	1.4	54
245	Long-Lasting Enfuvirtide Carrier Pentasaccharide Conjugates with Potent Anti-Human Immunodeficiency Virus Type 1 Activity. Antimicrobial Agents and Chemotherapy, 2010, 54, 134-142.	1.4	31
246	Different Evolution of Genotypic Resistance Profiles to Emtricitabine Versus Lamivudine in Tenofovir-Containing Regimens. Journal of Acquired Immune Deficiency Syndromes (1999), 2010, 55, 336-344.	0.9	32
247	Discovery of Novel Small Molecule Orally Bioavailable Câ^'Xâ^'C Chemokine Receptor 4 Antagonists That Are Potent Inhibitors of T-Tropic (X4) HIV-1 Replication. Journal of Medicinal Chemistry, 2010, 53, 3376-3388.	2.9	99
248	CXCR4 nanobodies (VHH-based single variable domains) potently inhibit chemotaxis and HIV-1 replication and mobilize stem cells. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 20565-20570.	3.3	202
249	Synthesis and Structureâ^'Activity Relationships of Azamacrocyclic C-X-C Chemokine Receptor 4 Antagonists: Analogues Containing a Single Azamacrocyclic Ring are Potent Inhibitors of T-Cell Tropic (X4) HIV-1 Replication. Journal of Medicinal Chemistry, 2010, 53, 1250-1260.	2.9	53
250	Citrullination of CXCL12 Differentially Reduces CXCR4 and CXCR7 Binding with Loss of Inflammatory and Anti-HIV-1 Activity via CXCR4. Journal of Immunology, 2009, 182, 666-674.	0.4	86
251	Human Immunodeficiency Virus Type 1 Escape from Cyclotriazadisulfonamide-Induced CD4-Targeted Entry Inhibition Is Associated with Increased Neutralizing Antibody Susceptibility. Journal of Virology, 2009, 83, 9577-9583.	1.5	10
252	Novel Recombinant Virus Assay for Measuring Susceptibility of Human Immunodeficiency Virus Type 1 Group M Subtypes To Clinically Approved Drugs. Journal of Clinical Microbiology, 2009, 47, 2232-2242.	1.8	13

#	Article	IF	Citations
253	In vitro synergistic activity against CCR5-tropic HIV-1 with combinations of potential candidate microbicide molecules HHA, KRV2110 and enfuvirtide (T20). Journal of Antimicrobial Chemotherapy, 2009, 64, 1192-1195.	1.3	12
254	The Phthalocyanine Prototype Derivative Alcian Blue Is the First Synthetic Agent with Selective Anti-Human Immunodeficiency Virus Activity Due to Its gp120 Glycan-Binding Potential. Antimicrobial Agents and Chemotherapy, 2009, 53, 4852-4859.	1.4	11
255	Antiviral activity of carbohydrate-binding agents and the role of DC-SIGN in dengue virus infection. Virology, 2009, 387, 67-75.	1.1	64
256	Capture and transmission of HIV-1 by the C-type lectin L-SIGN (DC-SIGNR) is inhibited by carbohydrate-binding agents and polyanions. Antiviral Research, 2009, 83, 61-70.	1.9	10
257	The candidate sulfonated microbicide, PRO 2000, has potential multiple mechanisms of action against HIV-1. Antiviral Research, 2009, 84, 38-47.	1.9	41
258	Total Synthesis of the Antiviral Peptide Antibiotic Feglymycin. Angewandte Chemie - International Edition, 2009, 48, 1856-1861.	7.2	48
259	Unsung Hero Robert C. Gallo. Science, 2009, 323, 206-207.	6.0	2
260	Macrocyclic polyamines inhibit HIV infection by interacting with the cellular HIV co-receptors CXCR4 and CCR5. Retrovirology, 2009, 6, .	0.9	0
261	Carbohydrate-binding agents (CBAs) inhibit HIV-1 infection in human primary monocyte-derived macrophages (MDMs) and efficiently prevent MDM-directed viral capture and subsequent transmission to CD4+ T lymphocytes. Virology, 2008, 370, 382-391.	1.1	32
262	Development and in vitro evaluation of chloroquine gels as microbicides against HIV-1 infection. Virology, 2008, 378, 306-310.	1.1	16
263	Safety concerns for the potential use of cyanovirin-N as a microbicidal anti-HIV agent. International Journal of Biochemistry and Cell Biology, 2008, 40, 2802-2814.	1.2	67
264	Resistance Mutations in Human Immunodeficiency Virus Type 1 Integrase Selected with Elvitegravir Confer Reduced Susceptibility to a Wide Range of Integrase Inhibitors. Journal of Virology, 2008, 82, 10366-10374.	1.5	153
265	Simian Immunodeficiency Virus Is Susceptible to Inhibition by Carbohydrate-Binding Agents in a Manner Similar to That of HIV: Implications for Further Preclinical Drug Development. Molecular Pharmacology, 2008, 74, 330-337.	1.0	11
266	CADA, a Potential Anti-HIV Microbicide that Specifically Targets the Cellular CD4 Receptor. Current HIV Research, 2008, 6, 246-256.	0.2	18
267	Diffusion of Two Potential Anti-HIV Microbicides across Intact and De-Epithelialised, Human Vaginal Mucosa. European Journal of Inflammation, 2008, 6, 17-23.	0.2	1
268	Viral Interactions in Human Lymphoid Tissue: Human Herpesvirus 7 Suppresses the Replication of CCR5-Tropic Human Immunodeficiency Virus Type 1 via CD4 Modulation. Journal of Virology, 2007, 81, 708-717.	1.5	59
269	Modest Human Immunodeficiency Virus Coreceptor Function of CXCR3 Is Strongly Enhanced by Mimicking the CXCR4 Ligand Binding Pocket in the CXCR3 Receptor. Journal of Virology, 2007, 81, 3632-3639.	1.5	11
270	Novel In Vivo Model for the Study of Human Immunodeficiency Virus Type 1 Transcription Inhibitors: Evaluation of New 6-Desfluoroquinolone Derivatives. Antimicrobial Agents and Chemotherapy, 2007, 51, 1407-1413.	1.4	19

#	Article	IF	Citations
271	Profound Anti-HIV-1 Activity of DAPTA in Monocytes/macrophages and Inhibition of CCR5-mediated Apoptosis in Neuronal Cells. Antiviral Chemistry and Chemotherapy, 2007, 18, 285-295.	0.3	5
272	Pradimicin A, a Carbohydrate-Binding Nonpeptidic Lead Compound for Treatment of Infections with Viruses with Highly Glycosylated Envelopes, Such as Human Immunodeficiency Virus. Journal of Virology, 2007, 81, 362-373.	1.5	99
273	Carbohydrate-Binding Agents Efficiently Prevent Dendritic Cell-Specific Intercellular Adhesion Molecule-3-Grabbing Nonintegrin (DC-SIGN)-Directed HIV-1 Transmission to T Lymphocytes. Molecular Pharmacology, 2007, 71, 3-11.	1.0	80
274	Molecular Mechanism of Action of Monocyclam Versus Bicyclam Non-peptide Antagonists in the CXCR4 Chemokine Receptor. Journal of Biological Chemistry, 2007, 282, 27354-27365.	1.6	104
275	Differential in vitro inhibitory activity against HIV-1 of alpha-(1-3)- and alpha-(1-6)-D-mannose specific plant lectins : Implication for microbicide development. Journal of Translational Medicine, 2007, 5, 28.	1.8	24
276	Design and cellular kinetics of dansyl-labeled CADA derivatives with anti-HIV and CD4 receptor down-modulating activity. Biochemical Pharmacology, 2007, 74, 566-578.	2.0	13
277	Resistance of HIV-1 to the broadly HIV-1-neutralizing, anti-carbohydrate antibody 2G12. Virology, 2007, 360, 294-304.	1.1	40
278	The role of N-glycosylation sites on the CXCR4 receptor for CXCL-12 binding and signaling and X4 HIV-1 viral infectivity. Virology, 2007, 363, 280-287.	1.1	27
279	Entry of hepatitis C virus and human immunodeficiency virus is selectively inhibited by carbohydrate-binding agents but not by polyanions. Virology, 2007, 366, 40-50.	1.1	70
280	Synthesis and Structureâ^'Activity Relationship Studies of CD4 Down-Modulating Cyclotriazadisulfonamide (CADA) Analogues. Journal of Medicinal Chemistry, 2006, 49, 1291-1312.	2.9	34
281	HIV coreceptor CXCR4 antagonists. Current Opinion in HIV and AIDS, 2006, 1, 361-366.	1.5	2
282	HIV co-receptor inhibitors as novel class of anti-HIV drugs. Antiviral Research, 2006, 71, 216-226.	1.9	41
283	Therapeutic strategies towards HIV-1 infection in macrophages. Antiviral Research, 2006, 71, 293-300.	1.9	39
284	Introduction to the Special Issue dedicated to Prof. Erik De Clercq for reaching the Professor Emeritus status at the Katholieke Universiteit Leuven. Antiviral Research, 2006, 71, 75-76.	1.9	1
285	Inhibitors of HIV Infection via the Cellular CD4 Receptor. Current Medicinal Chemistry, 2006, 13, 731-743.	1.2	22
286	Mutational Pathways, Resistance Profile, and Side Effects of Cyanovirin Relative to Human Immunodeficiency Virus Type 1 Strains with N-Glycan Deletions in Their gp120 Envelopes. Journal of Virology, 2006, 80, 8411-8421.	1.5	93
287	Mechanisms underlying activity of antiretroviral drugs in HIV-1-infected macrophages: new therapeutic strategies. Journal of Leukocyte Biology, 2006, 80, 1103-1110.	1.5	44
288	Pronounced in vitro and in vivo antiretroviral activity of 5-substituted 2,4-diamino-6-[2-(phosphonomethoxy)ethoxy] pyrimidines. Journal of Antimicrobial Chemotherapy, 2006, 59, 80-86.	1.3	27

#	Article	IF	Citations
289	AMD3465, a monomacrocyclic CXCR4 antagonist and potent HIV entry inhibitor. Biochemical Pharmacology, 2005, 70, 752-761.	2.0	122
290	Cyclotriazadisulfonamides: promising new CD4-targeted anti-HIV drugs. Journal of Antimicrobial Chemotherapy, 2005, 56, 270-272.	1.3	17
291	Carbohydrate-binding Agents Cause Deletions of Highly Conserved Glycosylation Sites in HIV GP120. Journal of Biological Chemistry, 2005, 280, 41005-41014.	1.6	108
292	Marked Depletion of Glycosylation Sites in HIV-1 gp120 under Selection Pressure by the Mannose-Specific Plant Lectins ofHippeastrumHybrid andGalanthus nivalis. Molecular Pharmacology, 2005, 67, 1556-1565.	1.0	62
293	Sugar-Binding Proteins Potently Inhibit Dendritic Cell Human Immunodeficiency Virus Type 1 (HIV-1) Infection and Dendritic-Cell-Directed HIV-1 Transfer. Journal of Virology, 2005, 79, 13519-13527.	1.5	53
294	Pyridine N-oxide derivatives: unusual anti-HIV compounds with multiple mechanisms of antiviral action. Journal of Antimicrobial Chemotherapy, 2005, 55, 135-138.	1.3	95
295	Anti-HIV agents targeting the interaction of gp120 with the cellular CD4 receptor. Expert Opinion on Investigational Drugs, 2005, 14, 1199-1212.	1.9	26
296	HIV chemokine receptor inhibitors as novel anti-HIV drugs. Cytokine and Growth Factor Reviews, 2005, 16, 659-677.	3.2	41
297	Pro-inflammatory properties of stromal cell-derived factor-1 (CXCL12) in collagen-induced arthritis. Arthritis Research and Therapy, 2005, 7, R1208.	1.6	91
298	HIV Co-receptors as Targets for Antiviral Therapy. Current Topics in Medicinal Chemistry, 2004, 4, 883-893.	1.0	51
299	Inhibition of Human Immunodeficiency Virus Replication by a Dual CCR5/CXCR4 Antagonist. Journal of Virology, 2004, 78, 12996-13006.	1.5	81
300	Apoptosis of Bystander T Cells Induced by Human Immunodeficiency Virus Type 1 with Increased Envelope/Receptor Affinity and Coreceptor Binding Site Exposure. Journal of Virology, 2004, 78, 4541-4551.	1.5	67
301	Profile of Resistance of Human Immunodeficiency Virus to Mannose-Specific Plant Lectins. Journal of Virology, 2004, 78, 10617-10627.	1.5	94
302	Mannose-Specific Plant Lectins from the Amaryllidaceae Family Qualify as Efficient Microbicides for Prevention of Human Immunodeficiency Virus Infection. Antimicrobial Agents and Chemotherapy, 2004, 48, 3858-3870.	1.4	147
303	In Vivo Evolution of X4 Human Immunodeficiency Virus Type 1 Variants in the Natural Course of Infection Coincides with Decreasing Sensitivity to CXCR4 Antagonists. Journal of Virology, 2004, 78, 2722-2728.	1.5	37
304	CADA, a novel CD4-targeted HIV inhibitor, is synergistic with various anti-HIV drugs in vitro. Aids, 2004, 18, 2115-2125.	1.0	67
305	Fluorescent CXCL12AF647 as a novel probe for nonradioactive CXCL12/CXCR4 cellular interaction studies. Cytometry, 2004, 61A, 178-188.	1.8	36
306	Establishment of a novel CCR5 and CXCR4 expressing CD4+ cell line which is highly sensitive to HIV and suitable for high-throughput evaluation of CCR5 and CXCR4 antagonists. Retrovirology, 2004, 1, 2.	0.9	44

#	Article	IF	Citations
307	Obligatory involvement of CD26/dipeptidyl peptidase IV in the activation of the antiretroviral tripeptide glycylprolylglycinamide (GPG-NH2). International Journal of Biochemistry and Cell Biology, 2004, 36, 1848-1859.	1.2	14
308	Safety, Pharmacokinetics, and Antiviral Activity of AMD3100, a Selective CXCR4 Receptor Inhibitor, in HIV-1 Infection. Journal of Acquired Immune Deficiency Syndromes (1999), 2004, 37, 1253-1262.	0.9	344
309	CD4 Down-Modulating Compounds with Potent Anti-HIV Activity. Current Pharmaceutical Design, 2004, 10, 1795-1803.	0.9	20
310	Evaluation of SDF-1/CXCR4-induced Ca2+ signaling by fluorometric imaging plate reader (FLIPR) and flow cytometry. Cytometry, 2003, 51A, 35-45.	1.8	63
311	Mutations at the CXCR4 interaction sites for AMD3100 influence anti-CXCR4 antibody binding and HIV-1 entry. FEBS Letters, 2003, 546, 300-306.	1.3	37
312	The Anti-HIV Potency of Cyclotriazadisulfonamide Analogs Is Directly Correlated with Their Ability to Down-Modulate the CD4 Receptor. Molecular Pharmacology, 2003, 63, 203-210.	1.0	54
313	Specific CD4 down-modulating compounds with potent anti-HIV activity. Journal of Leukocyte Biology, 2003, 74, 667-675.	1.5	22
314	The Antiviral Activity of the CXCR4 Antagonist AMD3100 Is Independent of the Cytokine-Induced CXCR4/HIV Coreceptor Expression Level. AIDS Research and Human Retroviruses, 2003, 19, 1135-1139.	0.5	10
315	Development of a Cell-Based Enzyme-Linked Immunosorbent Assay for High-Throughput Screening of HIV Type 1 Entry Inhibitors Targeting the Coreceptor CXCR4. AIDS Research and Human Retroviruses, 2003, 19, 947-955.	0.5	14
316	In Vivo Evolution of Human Immunodeficiency Virus Type 1 toward Increased Pathogenicity through CXCR4-Mediated Killing of Uninfected CD4 T Cells. Journal of Virology, 2003, 77, 5846-5854.	1.5	118
317	Identification of a Subset of Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus Strains Able To Exploit an Alternative Coreceptor on Untransformed Human Brain and Lymphoid Cells. Journal of Virology, 2003, 77, 6138-6152.	1.5	56
318	Synthesis of Anti-HIV CADA Compounds and Quantitative Structure-Activity Relationships for CD4 Down-Modulation. , 2003, , 119.		0
319	Reduced fitness of HIV-1 resistant to CXCR4 antagonists. Antiviral Therapy, 2003, 8, 1-8.	0.6	10
320	Reduced Fitness of HIV-1 Resistant to Cxcr4 Antagonists. Antiviral Therapy, 2003, 8, 1-8.	0.6	51
321	Interleukin-8 and Growth-Regulated Oncogene Alpha Mediate Angiogenesis in Kaposi's Sarcoma. Journal of Virology, 2002, 76, 11570-11583.	1.5	79
322	Impact of Cytokines on Replication in the Thymus of Primary Human Immunodeficiency Virus Type 1 Isolates from Infants. Journal of Virology, 2002, 76, 6929-6943.	1.5	42
323	A Human Immunodeficiency Virus Type 1 Isolate from an Infected Person Homozygous for CCR5Î”32 Exhibits Dual Tropism by Infecting Macrophages and MT2 Cells via CXCR4. Journal of Virology, 2002, 76, 3114-3124.	1.5	53
324	Polysulfonates Derived from Metal Thiolate Complexes as Inhibitors of HIV-1 and Various other Enveloped Viruses In Vitro. Antiviral Chemistry and Chemotherapy, 2002, 13, 185-195.	0.3	19

#	Article	IF	Citations
325	AMD3100, a CxCR4 Antagonist, Attenuates Allergic Lung Inflammation and Airway Hyperreactivity. American Journal of Pathology, 2002, 160, 1353-1360.	1.9	203
326	Chemokine receptor inhibition by AMD3100 is strictly confined to CXCR4. FEBS Letters, 2002, 527, 255-262.	1.3	395
327	Coreceptor Phenotype of Natural Human Immunodeficiency Virus with Nef Deleted Evolves In Vivo, Leading to Increased Virulence. Journal of Virology, 2002, 76, 6966-6973.	1.5	42
328	2-chloro-3-pyridin-3-yl-5,6,7,8-tetrahydroindolizine-1-carboxamide (CMV423), a new lead compound for the treatment of human cytomegalovirus infections. Antiviral Research, 2002, 55, 413-424.	1.9	46
329	Susceptibility of diverse primary HIV isolates with varying co-receptor specificity's to CXCR4 antagonistic compounds. Journal of Medical Virology, 2002, 68, 147-155.	2.5	8
330	CADA Inhibits Human Immunodeficiency Virus and Human Herpesvirus 7 Replication by Down-modulation of the Cellular CD4 Receptor. Virology, 2002, 302, 342-353.	1.1	63
331	Mutation of Asp¹⁷¹and Asp²⁶²of the Chemokine Receptor CXCR4 Impairs Its Coreceptor Function for Human Immunodeficiency Virus-1 Entry and Abrogates the Antagonistic Activity of AMD3100. Molecular Pharmacology, 2001, 60, 164-173.	1.0	123
332	HIV-1 gp120 and chemokine activation of Pyk2 and mitogen-activated protein kinases in primary macrophages mediated by calcium-dependent, pertussis toxinâ€“insensitive chemokine receptor signaling. Blood, 2001, 98, 2909-2916.	0.6	138
333	Antiviral agents active against human herpesviruses HHV-6, HHV-7 and HHV-8. Reviews in Medical Virology, 2001, 11, 381-395.	3.9	157
334	Diverging binding capacities of natural LD78Î² isoforms of macrophage inflammatory protein-1Î± to the CC chemokine receptors 1, 3 and 5 affect their anti-HIV-1 activity and chemotactic potencies for neutrophils and eosinophils. European Journal of Immunology, 2001, 31, 2170-2178.	1.6	91
335	Coreceptor Choice and T Cell Depletion by R5, X4, and R5X4 HIV-1 Variants in CCR5-Deficient (CCR5Î”32) and Normal Human Lymphoid Tissue. Virology, 2001, 281, 239-247.	1.1	20
336	Quantitative Evaluation of HIV-1 Coreceptor Use in the GHOST(3) Cell Assay. Virology, 2001, 291, 1-11.	1.1	35
337	Coreceptor Usage of Sequential Isolates from Cynomolgus Monkeys Experimentally Infected with Simian Immunodeficiency Virus (SIVsm). Virology, 2001, 291, 12-21.	1.1	15
338	CXCR4 is the primary receptor for feline immunodeficiency virus in astrocytes. Journal of NeuroVirology, 2001, 7, 487-492.	1.0	15
339	CXCR4-activated astrocyte glutamate release via TNFÎ±: amplification by microglia triggers neurotoxicity. Nature Neuroscience, 2001, 4, 702-710.	7.1	996
340	The LD78Î² Isoform of MIP-1Î± Is the Most Potent CC-Chemokine in Inhibiting CCR5-Dependent Human Immunodeficiency Virus Type 1 Replication in Human Macrophages. Journal of Virology, 2001, 75, 4402-4406.	1.5	50
341	No Selection for CCR5 Coreceptor Usage during Parenteral Transmission of Macrophagetropic Syncytium-Inducing Human Immunodeficiency Virus Type 1. Journal of Virology, 2001, 75, 8848-8853.	1.5	9
342	ACYCLIC/CARBOCYCLIC GUANOSINE ANALOGUES AS ANTI-HERPESVIRUS AGENTS. Nucleosides, Nucleotides and Nucleic Acids, 2001, 20, 271-285.	0.4	60

#	Article	IF	Citations
343	Productive Infection of Primary Macrophages with Human Herpesvirus 7. Journal of Virology, 2001, 75, 10511-10514.	1.5	13
344	AMD3100, a Potent and Specific Antagonist of the Stromal Cell-Derived Factor-1 Chemokine Receptor CXCR4, Inhibits Autoimmune Joint Inflammation in IFN-Î³ Receptor-Deficient Mice. Journal of Immunology, 2001, 167, 4686-4692.	0.4	245
345	Macrophage Tropism of Human Immunodeficiency Virus Type 1 Isolates from Brain and Lymphoid Tissues Predicts Neurotropism Independent of Coreceptor Specificity. Journal of Virology, 2001, 75, 10073-10089.	1.5	264
346	Chloroquine accumulates in breast-milk cells: potential impact in the prophylaxis of postnatal mother-to-child transmission of HIV-1. Aids, 2001, 15, 2205-2207.	1.0	27
347	Viral Entry as the Primary Target for the Anti-HIV Activity of Chicoric Acid and Its Tetra-Acetyl Esters. Molecular Pharmacology, 2000, 58, 641-648.	1.0	109
348	HIV-1 gp120 and chemokines activate ion channels in primary macrophages through CCR5 and CXCR4 stimulation. Proceedings of the National Academy of Sciences of the United States of America, 2000, 97, 4832-4837.	3.3	140
349	CXC-Chemokine Receptor 4 Is Not a Coreceptor for Human Herpesvirus 7 Entry into CD4+ T Cells. Journal of Virology, 2000, 74, 2011-2016.	1.5	10
350	Viral Entry through CXCR4 Is a Pathogenic Factor and Therapeutic Target in Human Immunodeficiency Virus Type 1 Disease. Journal of Virology, 2000, 74, 184-192.	1.5	65
351	Polyanionic (i.e., Polysulfonate) Dendrimers Can Inhibit the Replication of Human Immunodeficiency Virus by Interfering with Both Virus Adsorption and Later Steps (Reverse Transcriptase/Integrase) in the Virus Replicative Cycle. Molecular Pharmacology, 2000, 58, 1100-1108.	1.0	149
352	Potent Anti-HIV (Type 1 and Type 2) Activity of Polyoxometalates:Â Structureâ^'Activity Relationship and Mechanism of Action. Journal of Medicinal Chemistry, 2000, 43, 778-783.	2.9	65
353	Activity of Different Bicyclam Derivatives against Human Immunodeficiency Virus Depends on Their Interaction with the CXCR4 Chemokine Receptor. Molecular Pharmacology, 1999, 55, 67-73.	1.0	107
354	Coreceptor Ligand Inhibition of Fetal Brain Cell Infection by HIV Type 1. AIDS Research and Human Retroviruses, 1999, 15, 989-1000.	0.5	18
355	The Role of CD26/DPP IV in Chemokine Processing. , 1999, 72, 42-56.		80
356	Truncation of Macrophage-derived Chemokine by CD26/ Dipeptidyl-Peptidase IV beyond Its Predicted Cleavage Site Affects Chemotactic Activity and CC Chemokine Receptor 4 Interaction. Journal of Biological Chemistry, 1999, 274, 3988-3993.	1.6	142
357	Nuclear Localization of Human Immunodeficiency Virus Type 1 Integrase Expressed as a Fusion Protein with Green Fluorescent Protein. Virology, 1999, 258, 327-332.	1.1	74
358	Selective activity of various antiviral compounds against HHV-7 infection. Antiviral Research, 1999, 43, 23-35.	1.9	55
359	Synthesis and Structureâ^'Activity Relationships of Phenylenebis(methylene)- Linked Bis-azamacrocycles That Inhibit HIV-1 and HIV-2 Replication by Antagonism of the Chemokine Receptor CXCR4. Journal of Medicinal Chemistry, 1999, 42, 3971-3981.	2.9	107
360	Extension of the Polyanionic Cosalane Pharmacophore as a Strategy for Increasing Anti-HIV Potency. Journal of Medicinal Chemistry, 1999, 42, 1767-1777.	2.9	15

#	Article	IF	Citations
361	Shift of Clinical Human Immunodeficiency Virus Type 1 Isolates from X4 to R5 and Prevention of Emergence of the Syncytium-Inducing Phenotype by Blockade of CXCR4. Journal of Virology, 1999, 73, 5577-5585.	1.5	90
362	Bicyclams, Selective Antagonists of the Human Chemokine Receptor CXCR4, Potently Inhibit Feline Immunodeficiency Virus Replication. Journal of Virology, 1999, 73, 6346-6352.	1.5	65
363	Role of CXCR4 in Cell-Cell Fusion and Infection of Monocyte-Derived Macrophages by Primary Human Immunodeficiency Virus Type 1 (HIV-1) Strains: Two Distinct Mechanisms of HIV-1 Dual Tropism. Journal of Virology, 1999, 73, 7117-7125.	1.5	97
364	The LD78Î² isoform of MIP-1Î± is the most potent CCR5 agonist and HIV-1â€“inhibiting chemokine. Journal of Clinical Investigation, 1999, 104, R1-R5.	3.9	93
365	Preferential coreceptor utilization and cytopathicity by dual-tropic HIV-1 in human lymphoid tissue ex vivo. Journal of Clinical Investigation, 1999, 104, R7-R11.	3.9	83
366	AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor. Nature Medicine, 1998, 4, 72-77.	15.2	760
367	CD26-processed RANTES(3â€“68), but not intact RANTES, has potent anti-HIV-1 activity. Antiviral Research, 1998, 39, 175-187.	1.9	75
368	Processing by CD26/dipeptidyl-peptidase IV reduces the chemotactic and anti-HIV-1 activity of stromal-cell-derived factor-1Î±. FEBS Letters, 1998, 432, 73-76.	1.3	187
369	Polyanion Inhibitors of HIV and Other Viruses. 7. Polyanionic Compounds and Polyzwitterionic Compounds Derived from Cyclodextrins as Inhibitors of HIV Transmission. Journal of Medicinal Chemistry, 1998, 41, 4927-4932.	2.9	48
370	Amino-terminal Truncation of Chemokines by CD26/Dipeptidyl-peptidase IV. Journal of Biological Chemistry, 1998, 273, 7222-7227.	1.6	238
371	Human Immunodeficiency Virus Glycoprotein gp120 as the Primary Target for the Antiviral Action of AR177 (Zintevir). Molecular Pharmacology, 1998, 53, 340-345.	1.0	118
372	Determinants for Sensitivity of Human Immunodeficiency Virus Coreceptor CXCR4 to the Bicyclam AMD3100. Journal of Virology, 1998, 72, 6381-6388.	1.5	145
373	CXCR4 as a Functional Coreceptor for Human Immunodeficiency Virus Type 1 Infection of Primary Macrophages. Journal of Virology, 1998, 72, 8453-8457.	1.5	140
374	T-Cell-Line-Tropic Human Immunodeficiency Virus Type 1 That Is Made Resistant to Stromal Cell-Derived Factor 1Î± Contains Mutations in the Envelope gp120 but Does Not Show a Switch in Coreceptor Use. Journal of Virology, 1998, 72, 4032-4037.	1.5	100
375	Inhibition of T-tropic HIV Strains by Selective Antagonization of the Chemokine Receptor CXCR4. Journal of Experimental Medicine, 1997, 186, 1383-1388.	4.2	559
376	Anti-HIV Activities of Anionic Metalloporphyrins and Related Compounds. Antiviral Chemistry and Chemotherapy, 1997, 8, 85-97.	0.3	30
377	Development of Resistance of Human Immunodeficiency Virus Type 1 to Dextran Sulfate Associated with the Emergence of Specific Mutations in the Envelope gp120 Glycoprotein. Molecular Pharmacology, 1997, 52, 98-104.	1.0	73
378	Bicyclams, a class of potent anti-HIV agents, are targeted at the HIV coreceptor Fusin/CXCR-4. Antiviral Research, 1997, 35, 147-156.	1.9	223

#	Article	IF	Citations
379	Interactions of the HIV fusion inhibitor AR177 (ZINTEVIR) with the HIV type I second receptor. Antiviral Research, 1997, 34, A41.	1.9	0
380	Disulfide-containing macrolides that inhibit a late stage of the replicative cycle of human immunodeficiency virus. Antiviral Research, 1997, 34, A48.	1.9	0
381	Human immunodeficiency virus gp120 as the primary target of action of AR177 (Zintevir). Antiviral Research, 1997, 34, A57.	1.9	1
382	Polyanion Inhibitors of Human Immunodeficiency Virus and Other Viruses. Part 2. Polymerized Anionic Surfactants Derived from Amino Acids and Dipeptides. Journal of Medicinal Chemistry, 1996, 39, 1626-1634.	2.9	20
383	Mechanism of the Antiviral Activity of New Aurintricarboxylic Acid Analogues. Antiviral Chemistry and Chemotherapy, 1996, 7, 142-152.	0.3	14
384	Inhibition of Human IgE Synthesis in vitro and in SCID-hu Mice by an Interleukin-4 Receptor Antagonist. International Archives of Allergy and Immunology, 1995, 107, 304-307.	0.9	18
385	Differential antiviral activity of derivatized dextrans. Biochemical Pharmacology, 1995, 50, 743-751.	2.0	48
386	Modified Cyclodextrin Sulphates(mCDS11) have Potent Inhibitory Activity against HIV and High Oral Bioavailability. Antiviral Chemistry and Chemotherapy, 1994, 5, 155-161.	0.3	19
387	Anti-SCID mouse reactivity shapes the human CD4+ T cell repertoire in hu-PBL-SCID chimeras.. Journal of Experimental Medicine, 1994, 180, 1817-1827.	4.2	116
388	Lymphoid and myeloid differentiation of fetal liver CD34+lineage- cells in human thymic organ culture.. Journal of Experimental Medicine, 1994, 180, 123-132.	4.2	74
389	Inhibitory activity of S-adenosylhomocysteine hydrolase inhibitors against human cytomegalovirus replication. Antiviral Research, 1993, 21, 197-216.	1.9	41
390	Preparation and anti-HIV activity of O-acylated heparin and dermatan sulfate derivatives with low anticoagulant effect. Journal of Medicinal Chemistry, 1993, 36, 3546-3555.	2.9	35
391	Inhibition of HIV-1-Induced Cytopathogenicity, Syncytium Formation, and Virus-Cell Binding by Naphthalenedisulphonic Acids through Interaction with the Viral Envelope gp120 Glycoprotein. Antiviral Chemistry and Chemotherapy, 1993, 4, 229-234.	0.3	7
392	Potent and highly selective human immunodeficiency virus type 1 (HIV-1) inhibition by a series of alpha-anilinophenylacetamide derivatives targeted at HIV-1 reverse transcriptase.. Proceedings of the National Academy of Sciences of the United States of America, 1993, 90, 1711-1715.	3.3	203
393	New Polyacetal Polysulphate Active against Human Immunodeficiency Virus and other Enveloped Viruses. Antiviral Chemistry and Chemotherapy, 1992, 3, 351-360.	0.3	19
394	Differential Activity of Polyanionic Compounds and Castanospermine against HIV Replication and HIV-Induced Syncytium Formation Depending on Virus Strain and Cell Type. Antiviral Chemistry and Chemotherapy, 1992, 3, 23-29.	0.3	25
395	2',5'-Bis-O-(tert-butyldimethylsilyl)-3'-spiro-5''-(4''-amino-1'',2''- oxathiole-2'',2'-dioxide)pyrimidine (TSAO) nucleoside analogues: highlyselective inhibitors of human immunodeficiency virus type 1 that are targeted at the viral reverse transcriptase.. Proceedings of the National Academy of Sciences of the United States of America, 1992, 89, 4392-4396.	3.3	164
396	Sulfonic acid polymers as a new class of human immunodeficiency virus inhibitors. Antiviral Research, 1992, 18, 139-150.	1.9	68

#	Article	IF	Citations
397	The mannose-specific plant lectins from Cymbidium hybrid and Epipactis helleborine and the (N-acetylglucosamine)n-specific plant lectin from Urtica dioica are potent and selective inhibitors of human immunodeficiency virus and cytomegalovirus replication in vitro. Antiviral Research, 1992, 18, 191-207.	1.9	230
398	Flow cytometric method for the detection of gpI antigens of varicella zoster virus and evaluation of anti-VZV agents. Journal of Virological Methods, 1992, 38, 243-254.	1.0	23
399	Structure investigation and anti-HIV activities of high-molecular weight ATA polymers. Journal of Organic Chemistry, 1992, 57, 7241-7248.	1.7	20
400	Anti-human immunodeficiency virus effects of cationic metalloporphyrin-ellipticine complexes. Biochemical Pharmacology, 1992, 44, 1675-1679.	2.0	45
401	Sulfated polymers inhibit the interaction of human cytomegalovirus with cell surface heparan sulfate. Virology, 1992, 189, 48-58.	1.1	173
402	Presence of class II histocompatibility DR proteins on the envelope of human immunodeficiency virus demonstrated by FACS analysis. Virology, 1992, 189, 374-376.	1.1	71
403	Activity of different antiviral drug combinations against human cytomegalovirus replication in vitro. European Journal of Clinical Microbiology and Infectious Diseases, 1992, 11, 1144-1155.	1.3	31
404	Antiviral activity of anti-cytomegalovirus agents (HPMPC, HPMPA) assessed by a flow cytometric method and DNA hybridization technique. Antiviral Research, 1991, 16, 1-9.	1.9	30
405	Preparation and anti-HIV activities of aurintricarboxylic acid fractions and analogs: direct correlation of antiviral potency with molecular weight. Journal of Medicinal Chemistry, 1991, 34, 329-337.	2.9	80
406	1-Î²-D-Ribofuranosyl-1,2,4-triazole-3-carboxamide (ribavirin) and 5-ethynyl-1-Î²-D-ribofuranosylimidazole-4-carboxamide (EICAR) markedly potentiate the inhibitory effect of 2â€²,3â€²-dideoxyinosine on human immunodeficiency virus in peripheral blood lymphocytes. Biochemical and Biophysical Research Communications, 1991, 178, 563-569.	1.0	31
407	Activity of acyclic nucleoside phosphonate analogues against human immunodeficiency virus in monocyte/macrophages and peripheral blood lymphocytes. Biochemical and Biophysical Research Communications, 1991, 178, 329-335.	1.0	55
408	Sensitive, reproducible and convenient fluorometric assay for the in vitro evaluation of anticytomegalovirus agents. Journal of Virological Methods, 1991, 35, 27-38.	1.0	22
409	Synthesis and anti-HIV activities of low molecular weight aurintricarboxylic acid fragments and related compounds. Journal of Medicinal Chemistry, 1991, 34, 337-342.	2.9	61
410	Comparative activity of selected antiviral compounds against clinical isolates of human cytomegalovirus. European Journal of Clinical Microbiology and Infectious Diseases, 1991, 10, 1026-1033.	1.3	68
411	Antiviral Activity of low-MW Dextran Sulphate (Derived from dextran MW 1000) Compared to Dextran Sulphate Samples of Higher MW. Antiviral Chemistry and Chemotherapy, 1991, 2, 171-179.	0.3	54
412	Sulphated Cyclodextrins are Potent anti-HIV Agents Acting Synergistically with 2â€²,3â€²-dideoxynucleoside Analogues. Antiviral Chemistry and Chemotherapy, 1991, 2, 45-53.	0.3	41
413	Inhibitory Effects of Polycations on the Replication of Enveloped Viruses (HIV, HSV, CMV, RSV,) Tj ETQq1 1 0.784314 rgBT /Overlock 10 243-248.	0.3	18
414	Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives. Nature, 1990, 343, 470-474.	13.7	794

#	Article	IF	Citations
415	Selective inhibition of human cytomegalovirus DNA synthesis by (S)-1-(3-Hydroxy-2-phosphonylmethoxypropyl)cytosine [(S)-HPMPC] and 9-(1,3-Dihydroxy-2-propoxymethyl)guanine (DHPG). Virology, 1990, 179, 41-50.	1.1	92
416	Dextran sulfate and other polyanionic anti-HIV compounds specifically interact with the viral gp120 glycoprotein expressed by T-cells persistently infected with HIV-1. Virology, 1990, 175, 556-561.	1.1	217
417	Flow cytometric method to monitor the destruction of CD4+ cells following their fusion with HIV-infected cells. Cytometry, 1990, 11, 736-743.	1.8	19
418	Sulphated Polymers are Potent and Selective Inhibitors of Various Enveloped Viruses, Including Herpes Simplex Virus, Cytomegalovirus, Vesicular Stomatitis Virus, Respiratory Syncytial Virus, and Toga-, Arena- and Retroviruses. Antiviral Chemistry and Chemotherapy, 1990, 1, 233-240.	0.3	85
419	Anti-HIV-1 activity of antiviral compounds, as quantitated by a focal immunoassay in CD4+ HeLa cells and a plaque assay in MT-4 cells. Journal of Virological Methods, 1990, 29, 197-208.	1.0	21
420	Syncytium Formation and Destruction of Bystander CD4+ Cells Cocultured with T Cells Persistently Infected with Human Immunodeficiency Virus as Demonstrated by Flow Cytometry. Journal of General Virology, 1989, 70, 2397-2408.	1.3	49
421	Detection of immediate early, early and late antigens of human cytomegalovirus by flow cytometry. Journal of Virological Methods, 1989, 26, 247-254.	1.0	32
422	Tetrazolium-based plaque assay for HIV-1 and HIV-2, and its use in the evaluation of antiviral compounds. Journal of Virological Methods, 1989, 26, 319-329.	1.0	36
423	Highly specific inhibition of human immunodeficiency virus type 1 by a novel 6-substituted acyclouridine derivative. Biochemical and Biophysical Research Communications, 1989, 165, 1375-1381.	1.0	294
424	Specific interaction of aurintricarboxylic acid with the human immunodeficiency virus/CD4 cell receptor.. Proceedings of the National Academy of Sciences of the United States of America, 1989, 86, 3322-3326.	3.3	118
425	A highly reliable, sensitive, flow cytometric/fluorometric assay for the evaluation of the anti-HIV activity of antiviral compounds in MT-4 cells. Journal of Immunological Methods, 1988, 114, 27-32.	0.6	28
426	Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds. Journal of Virological Methods, 1988, 20, 309-321.	1.0	1,644
427	Fuchsin acid selectively inhibits human immunodeficiency virus (HIV) replication invitro. Biochemical and Biophysical Research Communications, 1988, 155, 1404-1411.	1.0	48
428	Pentosan polysulfate, a sulfated oligosaccharide, is a potent and selective anti-HIV agent in vitro. Antiviral Research, 1988, 9, 335-343.	1.9	195
429	Immunocytochemical demonstration of proopiomelanocortin- and other opioid-related substances and a CRF-like peptide in the gut of the american cockroach, Periplaneta americana L.. Histochemistry, 1987, 86, 345-351.	1.9	38
430	Broad Antiviral Activity of Carbohydrate-Binding Agents Against Dengue Virus Infection. , 0, , .		0
431	In-Depth Characterization of Zika Virus Inhibitors Using Cell-Based Electrical Impedance. Microbiology Spectrum, 0, , .	1.2	4